News Merck, Pfizer and Gilead all interested in Medivation buy-ou... Sanofi has competition in its bid to acquire cancer specialist
News Zepatier to add competition to Europe’s hep C market Will company pursue same aggressive pricing strategy in Europe?
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News German pricing changes to hit blockbuster revenues But pharma will be able to negotiate confidential prices.
News Takeda gets first OK for orexin narcolepsy drug, in China China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
